C2i Genomics and Riken Genesis to Expand AI-Powered Whole-Genome MRD CancerDetection Technology Across JapanThe collaboration will expand C2i’s global reach and bring MRD cancer monitoring capabilities for solidtumors to JapanNEW YORK (March 2, 2023) — C2i Genomics, a cancer intelligence company, today announced acollaboration with Riken Genesis Co., Ltd. (RG), a company specializing in providing the service of
personalized medicine based on contract analysis of next-generation sequencing and exomes. The twocompanies have entered a collaboration agreement to bring MRD cancer monitoring to Japan forpharmaceutical and clinical research.
In Japan, the probability that people will be diagnosed with cancer in their lifetime (based on 2019 data) is
65.5% for men (1 in 2) and 51.2% for women (1 in 2). With a continuous increase in cancer incidence
over the last few decades, Japan’s growing need and implementation of well-equipped labs utilizing MRD
cancer monitoring will enable physicians to provide more personalized cancer detection and treatment
options for their patients.
Under this agreement, RG will work with C2i Genomics to commercialize its C2intelligence cloud-based
platform and the C2inform MRD test for pharmaceutical and clinical research and eventually forcommercial clinical testing in Japan. C2i’s technology allows cancer tumor burden monitoring using ultrasensitive whole genome sequencing (WGS) for personalized medicine and accelerated drugdevelopment. This collaboration will build on RG’s current capabilities to provide MRD detection forhematology by expanding its MRD capabilities across all solid tumors.
“We are pleased to partner with C2i Genomics to bring innovative molecular assays to the medicalcommunity in Japan. C2i Genomics’s sophisticated assays will be an important addition to our portfolio ofdiagnostic tests,” said Kenji Iwakabe, President and CEO at Riken Genesis.
RG provides lab-assay services and products for genetic testing based on cutting-edge gene analysis
technologies and bioinformatics. The company engages in four businesses: pharmaceutical development
support, gene contract analysis, and reagents and diagnostic reagents.
“As our reach expands to Japan, this collaboration will drastically increase the speed and availability inwhich C2i’s solution is utilized globally—directly affecting the lives of cancer patients for the better as wework toward providing easy accessibility to personalized medicine across the globe,” said Asaf Zviran,
CEO and co-founder of C2i Genomics.
Through WGS, growing genomic and clinical databases, and sophisticated computation and AI, C2i
enables high-precision personalized medicine, reduced cancer treatment costs, and accelerated drugdevelopment. Leveraging the thousands of already installed genome sequencers around the world, C2i
Genomics’ partner labs can process and sequence their own samples, upload the raw sequencing data toa server that C2i provides in their own country, and receive a report within days with their patient’streatment response estimation and risk of recurrence.
Now in Japan through the company’s agreement with RG, this collaboration follows several C2i
Genomics global partnerships, most recently with AstraZeneca in the US, Karkinos Healthcare in India,OncoDNA across the EU, and South East Asia with NovogeneAIT Genomics.

For companies interested in deploying C2i Genomics, please visit www.c2i-genomics.com.
About Riken Genesis Co., Ltd.
Riken Genesis, established in October 2007, provides products for genetic testing based on cutting-edge
genetic analysis technology and laboratory assay services with the mission of realizing precision
medicine based on genome science and molecular diagnostics technology. We offer reliable trials basedon international quality standards in laboratories that have obtained ISO 15189 certification, and we havea track record in clinical sequences, support for drug discovery research, and support for clinicalresearch. Please refer to the Riken Genesis website (URL: https://www.rikengenesis.jp/) for more
information.
About C2i Genomics:
Founded in 2019, C2i Genomics has created the world’s leading cancer treatment intelligence platformthat uses low-input blood (only 3-4mL blood) and offers ultra-sensitive whole-genome sequencing cancer
detection and monitoring. With headquarters in NYC, CLIA lab in Cambridge MA, and an R&D center inIsrael, C2i’s SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring ona global scale, leveraging the thousands of already installed genome sequencers around the world. Using
cutting-edge scientific breakthroughs, growing genomic and clinical databases, and sophisticatedcomputation and AI, C2i enables high-precision personalized medicine, reduced cancer treatment costs,and accelerated drug development. C2i was named to the 2021 CB Insights Digital 150 list and awarded
the 2022 North American Digital Cancer Monitoring Platform Technology Innovation Leadership Award by
Frost & Sullivan. For more information, please visit www.c2i-genomics.com.
Media Contact
Kayla Abbassi
PR for C2i Genomics
c2i@vsc.co